We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App




FABP4 Concentrations Quantified in Proliferative Diabetic Retinopathy

By LabMedica International staff writers
Posted on 07 Jul 2021
Print article
Image: Enzyme-linked immunosorbent assay (ELISA) kit for Fatty acid-binding proteins 4 (FABP4) (Photo courtesy of Biovendor R&D)
Image: Enzyme-linked immunosorbent assay (ELISA) kit for Fatty acid-binding proteins 4 (FABP4) (Photo courtesy of Biovendor R&D)
Proliferative diabetic retinopathy (PDR), a progressive and serious stage of diabetic retinopathy (DR) due to retinal ischemia, is characterized by neovascularization (NV), vitreous hemorrhaging (VH) and tractional retinal detachment (TRD), all of which are major causes of blindness in patients with diabetes mellitus (DM).

Fatty acid-binding proteins (FABPs) that act as intracellular lipid chaperones are a group of molecules that coordinate lipid responses in cells. Among the currently known FABPs, the FABP4, known as adipocyte FABP (A-FABP) or aP2, is expressed in both adipocytes and macrophages, and can be detected in most bodily fluids.

Scientists specializing in Ophthalmology at the Sapporo Medical University School of Medicine (Sapporo, Japan) and their colleagues recruited 20 PDR patients (mean age 63.27 ± 11.9 years; 10 males and 10 females), and 20 non-DR patients (mean age 69.2 ± 9.1 years; eight males and 12 females). Body height and weight measurements, blood pressure measurements and the collection of peripheral blood specimens for a complete blood count and biochemical analyses were performed.

The team performed biochemistry measurements of the vitreous concentrations of FABP4 (V-FABP4) or vascular endothelial growth factor A (V-VEGFA) and several blood chemistry analyses including plasma glucose levels, hemoglobin A1c (HbA1c), creatinine (Cr), blood urea nitrogen (BUN), uric acid, aspartate transaminase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP), lipid profiles, including total cholesterol and triglycerides, high-sensitivity C-reactive protein (hsCRP) and estimated glomerular filtration rate (eGFR). The concentrations of V-FABP4 (ng/mg protein) or V-VEGFA (pg/mg protein) were determined by enzyme-linked immunosorbent assay for FABP4 (Biovendor R&D, Modrice, Czech Republic) or human VEGFA (Fuji film Wako. Co., Osaka, Japan), respectively.

The investigators reported that the levels of V-FABP4 and V-VEGFA were significantly higher in PDR patients than in non-PDR patients with a high positive correlation between them. The findings were not affected by body mass index values and the presence of vitreous hemorrhaging. Among the clinical parameters, V-FABP4 correlated positively with creatinine and negatively with age and aspartate transaminase (AST) levels, while V-VEGFA correlated positively with fasting plasma glucose and hemoglobin A1c (HbA1c) levels, but negatively with AST. Multiple regression analyses indicated that V-VEGFA, or V-FABP4, AST and HbA1c were independent predictors of V-FABP4 or V-VEGFA, respectively. Both were negatively correlated, but more evident in V-FABP4, with the optic nerve head (ONH) ocular blood flow.

The authors concluded that the concentrations of both V-FABP4 and V-VEGFA were substantially elevated in eyes with PDR, and a significantly higher positive correlation was observed between them. However, correlation analyses and stepwise multiple regression analyses for V-FABP and V-VEGFA strongly suggested that both factors were independently regulated, suggesting that V-FABP4 might also be involved in the pathogenesis of PDR. The study was published on June 11, 2021 in the journal Scientific Reports.

Related Links:
Sapporo Medical University School of Medicine
Biovendor R&D
Fuji film Wako. Co


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.